Skip to main content
Figure 2 | Vascular Cell

Figure 2

From: Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia

Figure 2

blot analysis using Akt and pAkt were conducted on Tsc2 ang1 cells treated with treated with DMSO, rapamycin5nM, imatinib10uM or rapamycin5nM + imatinib10uM for 24 hours. Cells were lysed and analyzed by using antibodies specific for the total Akt and pAkt473. Rapamycin + imatinib treatment downregulates pAkt levels (p <0.0002). GAPDH was used as the loading control by using monoclonal anti-GAPDH antibody. All treatment groups were significant when compared to the vehicle control, Imatinib 10nM (p < 0.0006); Rapamycin 5nM (p < 0.0076); Rapamycin 5nM + Imatinib 10nM (p < 0.0002). However, the combinational therapy only show significance against Rapamycin at 5nM (p < 0.0243) and not Imatinib at 10nM (p < 0.4273).

Back to article page

Vascular Cell

ISSN: 2045-824X

Contact us